| 103 | 0 | 156 |
| 下载次数 | 被引频次 | 阅读次数 |
肠道病毒病是由肠道病毒（Enterovirus, EV）感染引起的一组疾病，从传统的脊髓灰质炎（Poliomyelitis）到现今常见的手足口病（Hand, foot, and mouth disease, HFMD），一直是全球公共卫生领域的重要问题。在肠道病毒病防控过程中，口服脊髓灰质炎减毒活疫苗（Oral poliovirus vaccine, OPV）和注射脊髓灰质炎灭活疫苗（Inactive poliovirus vaccine, IPV）为全球根除脊髓灰质炎行动（Global polio eradication initiative, GPEI）提供了有力支持，同时，肠道病毒病疫情监测体系的建立也有效提升了应对能力。然而，肠道病毒病的疾病负担依然较重，其传播途径多样，且病毒基因组易变异，导致防控工作面临持续挑战。本文介绍肠道病毒病的基本特征与防控现状，强调加强防控的必要性，并提出相应策略，为疾病防控和公共卫生风险管理提供参考。
Abstract：Enterovirus diseases are a group of illnesses caused by infection with enteroviruses(EVs). Ranging from the classical poliomyelitis to the more prevalent hand, foot, and mouth disease(HFMD), these infections have long posed major global public health challenges. The oral poliovirus vaccine(OPV) and inactivated poliovirus vaccine(IPV) have played pivotal roles in supporting the Global Polio Eradication Initiative(GPEI), while the establishment of enterovirus surveillance systems has markedly enhanced outbreak detection and response capacity. Nevertheless, the disease burden of enterovirus infections remains substantial. Their multiple transmission routes and the high mutability of viral genomes continue to hinder effective prevention and control. This review outlines the key characteristics and current status of enterovirus disease prevention and control, emphasizes the need for strengthened measures, and proposes innovative strategies to guide future disease control and public-health risk management.
[1] Zell R, Delwart E, Gorbalenya AE, et al. ICTV virus taxonomy profile:Picornaviridae[J]. J Gen Virol,2017, 98(10):2421-2422. DOI:10. 1099/jgv. 0. 000911.
[2] Zhu P, Ji W, Li D, et al. Current status of hand-footand-mouth disease[J]. J Biomed Sci, 2023, 30(1):15. DOI:10. 1186/s12929-023-00908-4.
[3] Walter K, Malani PN. What is polio[J]. Jama, 2022,328(16):1652. DOI:10. 1001/jama. 2022. 17159.
[4] Bhasin VK, Lathika N. Polio vaccines[J]. Nature,1995, 376(6540):458. DOI:10. 1038/376458c0.
[5] Centers for Disease Control and Prevention(CDC).One thousand days until the target date for global poliomyelitis eradication[J]. MMWR Morb Mortal Wkly Rep, 1998, 47(12):234.
[6] Sáez-Llorens X, Bandyopadhyay AS, Gast C, et al.Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants:two clinical trials[J]. Lancet, 2021, 397(10268):27-38. DOI:10. 1016/s0140-6736(20)32540-x.
[7] Van Damme P, De Coster I, Bandyopadhyay AS, et al. The safety and immunogenicity of two novel live attenuated monovalent(serotype 2)oral poliovirus vaccines in healthy adults:a double-blind, single-centre phase 1 study[J]. Lancet, 2019, 394(10193):148-158. DOI:10. 1016/s0140-6736(19)31279-6.
[8] Guo H, Li Y, Liu G, et al. A second open reading frame in human enterovirus determines viral replication in intestinal epithelial cells[J]. Nat Commun, 2019,10:4066. DOI:10. 1038/s41467-019-12040-9.
[9] Lulla V, Dinan AM, Hosmillo M, et al. An upstream protein-coding region in enteroviruses modulates virus infection in gut epithelial cells[J]. Nat Microbiol, 2019,4(2):280-292. DOI:10. 1038/s41564-018-0297-1.
[10]Matsuura K, Ishikura M, Nakayama T, et al.Ecological studies on reovirus pollution of rivers in Toyama prefecture[J]. Microbiol Immunol, 1988, 32(12):1221-1234. DOI:10. 1111/j. 1348-0421. 1988.tb01486. x.
[11]Abedi GR, Watson JT, Nix WA, et al. Enterovirus and parechovirus surveillance—United States, 2014–2016[J]. MMWR Morb Mortal Wkly Rep, 2018, 67(18):515-518. DOI:10. 15585/mmwr. mm6718a2.
[12]Fall A, Norton JM, Abdullah O, et al. Enhanced genomic surveillance of enteroviruses reveals a surge in enterovirus D68 cases, the Johns Hopkins health system, Maryland, 2024[J]. J Clin Microbiol, 2025,63(7):e00469-e00425. DOI:10. 1128/jcm. 00469-25.
[13]Hong J, Liu F, Qi H, et al. Changing epidemiology of hand, foot, and mouth disease in China, 2013–2019:a population-based study[J]. Lancet Reg Health West Pac, 2022, 20:100370. DOI:10. 1016/j.lanwpc. 2021. 100370.
[14]Kamau E, Nguyen D, Celma C, et al. Seroprevalence and virologic surveillance of enterovirus 71 and coxsackievirus A6, United Kingdom, 2006–2017[J].Emerg Infect Dis, 2021, 27(9):2261-2268. DOI:10. 3201/eid2709. 204915.
[15]Kamau E, Lambert B, Allen DJ, et al. Enterovirus A71 and coxsackievirus A6 circulation in England, UK,2006–2017:a mathematical modelling study using cross-sectional seroprevalence data[J]. PLoS Pathog, 2024,20(11):e1012703. DOI:10. 1371/journal.ppat. 1012703.
[16]Bubba L, Broberg EK, Jasir A, et al. Circulation of non-polio enteroviruses in 24 EU and EEA countries between 2015 and 2017:a retrospective surveillance study[J]. Lancet Infect Dis, 2020, 20(3):350-361.DOI:10. 1016/s1473-3099(19)30566-3.
[17]Xiao J, Wang J, Zhang Y, et al. Coxsackievirus B4:an underestimated pathogen associated with a hand, foot,and mouth disease outbreak[J]. Arch Virol, 2021, 166(8):2225-2234. DOI:10. 1007/s00705-021-05128-5.
[18]Ji H, Fan H, Lu PX, et al. Surveillance for severe hand, foot, and mouth disease from 2009 to 2015 in Jiangsu Province:epidemiology, etiology, and disease burden[J]. BMC Infect Dis, 2019, 19(1):79. DOI:10. 1186/s12879-018-3659-7.
[19]Kanbayashi D, Kaida A, Yamamoto SP, et al. Impact of Coxsackievirus A6 emergence on hand, foot, and mouth disease epidemic in Osaka City, Japan[J]. J Med Virol, 2017, 89(12):2116-2121. DOI:10. 1002/jmv. 24905.
[20]Foster CB, Friedman N, Carl J, et al. Enterovirus D68:a clinically important respiratory enterovirus[J].Clevel Clin J Med, 2015, 82(1):26-31. DOI:10. 3949/ccjm. 82a. 14166.
[21]Zhang Y, Tan XJ, Wang HY, et al. An outbreak of hand, foot, and mouth disease associated with subgenotype C4 of human enterovirus 71 in Shandong,China[J]. J Clin Virol, 2009, 44(4):262-267. DOI:10. 1016/j. jcv. 2009. 02. 002.
[22]Xiao J, Huang K, Lu H, et al. Genomic epidemiology and phylodynamic analysis of enterovirus A71 reveal its transmission dynamics in Asia[J]. Microbiol Spectr,2022, 10(5):e01958-e01922. DOI:10. 1128/spectrum. 01958-22.
[23]路环环，肖金波，严冬梅，等. 2012-2023年882例重症手足口病病例病原谱及CV-A6基因特征分析[J].病毒学报，2024,40(02):383-391. DOI:10. 13242/j. cnki.bingduxuebao. 004470.
[24]傅荔艳，葛盈露，马婉婉，等. 2016-2020年安徽省手足口病流行病学特征及CVA6基因进化分析[J].病毒学报，2023,39(02):445-452. DOI:10. 13242/j. cnki.bingduxuebao. 004239.
[25]Lian H, Yi L, Qiu M, et al. Genomic epidemiology of CVA10 in Guangdong, China, 2013–2021[J]. Virol J, 2024, 21(1):122. DOI:10. 1186/s12985-024-02389-9.
[26]Li F, Zhang Q, Xiao J, et al. Epidemiology of hand,foot, and mouth disease and genetic characterization of coxsackievirus A16 in Shenyang, Liaoning Province,China, 2013–2023[J]. Viruses, 2024, 16(11):1666.DOI:10. 3390/v16111666.
[27]Li F, Zhang Q, Xiao J, et al. Epidemiology of hand,foot, and mouth disease and genetic characterization of coxsackievirus A16 in Shenyang, Liaoning Province,China, 2013–2023[J]. Viruses, 2024, 16(11):1666.DOI:10. 3390/v16111666.[LinkOut]
[28]肖金波，于秋丽，张勇，等. 2017~2018年河北省重症手足口病的主要致病病原体为柯萨奇病毒A组6型[J].病毒学报，2020,36(02):192-200. DOI:10. 13242/j.cnki. bingduxuebao. 003660.
[29]Jia J, Kong F, Xin X, et al. Epidemiological characteristics of hand, foot, and mouth disease outbreaks in Qingdao, 2009-2018[J]. Ijph, 2021, 50(5):999-1008. DOI:10. 18502/ijph. v50i5. 6117
[30]Victori E, Ventura RJ, Blanco MZ, et al. School outbreak of hand, foot and mouth disease in Northern Luzon, Philippines, October 2022[J]. West Pac Surveillance Response J, 2023, 14(2):35-39. DOI:10. 5365/wpsar. 2023. 14. 2. 1001.
[31]KHURI-BULOS N, MELNICK J L, HATCH M H,et al. The paralytic poliomyelitis epidemic of 1978 in Jordan:epidemiological implications[J]. Bulletin of the World Health Organization, 1984, 62(1):83-8.
[32]Novello F, Lombardi F, Amato C, et al. Paralytic poliomyelitis in Italy(1981–85)[J]. Eur J Epidemiol,1987, 3(1):54-60. DOI:10. 1007/BF00145073.
[33]Yu H, Li XW, Liu QB, et al. Diagnosis and treatment of herpangina:Chinese expert consensus[J]. World J Pediatr, 2020, 16(2):129-134. DOI:10. 1007/s12519-019-00277-9.
[34]Zhao TS, Du J, Li HJ, et al. Molecular epidemiology and clinical characteristics of herpangina children in Beijing, China:a surveillance study[J]. PeerJ, 2020,8:e9991. DOI:10. 7717/peerj. 9991.
[35]Ai Y, Zhang W, Wu J, et al. Molecular epidemiology and clinical features of enteroviruses-associated hand,foot, and mouth disease and herpangina outbreak in Zunyi, China, 2019[J]. Front Med, 2021, 8:656699.DOI:10. 3389/fmed. 2021. 656699.
[36]Mirand A, Henquell C, Archimbaud C, et al. Outbreak of hand, foot and mouth disease/herpangina associated with coxsackievirus A6 and A10 infections in 2010,France:a large citywide, prospective observational study[J]. Clin Microbiol Infect, 2012, 18(5):E110-E118.DOI:10. 1111/j. 1469-0691. 2012. 03789. x.
[37]Chansaenroj J, Auphimai C, Puenpa J, et al. High prevalence of coxsackievirus A2 in children with herpangina in Thailand in 2015[J]. VirusDisease,2017, 28(1):111-114. DOI:10. 1007/s13337-017-0366-8.
[38]Shah MM, Perez A, Lively JY, et al. Enterovirus D68-associated acute respiratory illness─new vaccine surveillance network, United States, July–November2018–2020[J]. MMWR Morb Mortal Wkly Rep,2021, 70(47):1623-1628. DOI:10. 15585/mmwr.mm7047a1.
[39]Greninger AL, Naccache SN, Messacar K, et al. A novel outbreak enterovirus D68 strain associated with acute flaccid myelitis cases in the USA(2012–14):a retrospective cohort study[J]. Lancet Infect Dis, 2015,15(6):671-682. DOI:10. 1016/s1473-3099(15)70093-9.
[40]Messacar K, Abzug MJ, Dominguez SR. 2014outbreak of enterovirus D68 in North America[J]. J Med Virol, 2016, 88(5):739-745. DOI:10. 1002/jmv. 24410.
[41]Dyda A, Stelzer-Braid S, Adam D, et al. The association between acute flaccid myelitis(AFM)and Enterovirus D68(EV-D68)–what is the evidence for causation[J]. Eurosurveillance, 2018, 23(3)17-00310. DOI:10. 2807/1560-7917. es. 2018. 23. 3. 17-00310
[42]Maruo Y, Nakanishi M, Suzuki Y, et al. Outbreak of aseptic meningitis caused by echovirus 30 in Kushiro,Japan in 2017[J]. J Clin Virol, 2019, 116:34-38.DOI:10. 1016/j. jcv. 2019. 05. 001.
[43]Wang J, Meng M, Xu H, et al. Analysis of enterovirus genotypes in the cerebrospinal fluid of children associated with aseptic meningitis in Liaocheng, China, from 2018to 2019[J]. BMC Infect Dis, 2021, 21(1):405. DOI:10. 1186/s12879-021-06112-9.
[44]Li J, Huang F, Zhang Y, et al. Molecular analysis of Coxsackievirus A24 variant isolates from three outbreaks of acute hemorrhagic conjunctivitis in 1988, 1994 and2007 in Beijing, China[J]. Virol Sin, 2022, 37(2):168-176. DOI:10. 1016/j. virs. 2022. 01. 024.
[45]Maitreyi RS, Dar L, Muthukumar A, et al. Acute hemorrhagic conjunctivitis due to enterovirus 70 in India[J]. Emerg Infect Dis, 1999, 5(2):267-269. DOI:10. 3201/eid0502. 990212.
[46]Lasrado N, Reddy J. An overview of the immune mechanisms of viral myocarditis[J]. Rev Med Virol,2020, 30(6):1-14. DOI:10. 1002/rmv. 2131.
[47]Zhang Y, Zhou X, Chen S, et al. Immune mechanisms of group B coxsackievirus induced viral myocarditis[J].Virulence, 2023, 14:2180951. DOI:10. 1080/21505594. 2023. 2180951.
[48]Bandyopadhyay AS, Modlin JF, Wenger J, et al.Immunogenicity of new primary immunization schedules with inactivated poliovirus vaccine and bivalent oral polio vaccine for the polio endgame:a review[J]. Clin Infect Dis, 2018, 67(suppl_1):S35-S41. DOI:10. 1093/cid/ciy633.
[49]Ciapponi A, Bardach A, Rey Ares L, et al. Sequential inactivated(IPV)and live oral(OPV)poliovirus vaccines for preventing poliomyelitis[J]. Cochrane Database Syst Rev, 2019, 2019(12):Cd011260. DOI:10. 1002/14651858. cd011260
[50]Shampo MA, Kyle RA. Jonas E. Salk—discoverer of a vaccine against poliomyelitis[J]. Mayo Clin Proc,1998, 73(12):1176. DOI:10. 4065/73. 12. 1176.
[51]Horaud F. Albert B. sabin and the development of oral poliovaccine[J]. Biologicals, 1993, 21(4):311-316.DOI:10. 1006/biol. 1993. 1089.
[52]Liang ZL, Mao QY, Wang YP, et al. Progress on the research and development of inactivated EV71 wholevirus vaccines[J]. Hum Vaccines Immunother, 2013, 9(8):1701-1705. DOI:10. 4161/hv. 24949.
[53]Huang LM, Chiu CH, Chiu NC, et al.Immunogenicity, safety, cross-reaction, and immune persistence of an inactivated enterovirus A71 vaccine in children aged from two months to 11 years in Taiwan[J]. Vaccine, 2019, 37(13):1827-1835. DOI:10. 1016/j. vaccine. 2019. 02. 023.
[54]Tong Y, Zhang X, Chen J, et al. Immunogenicity and safety of an enterovirus 71 vaccine in children aged 36-71months:a double-blind, randomised, similar vaccinecontrolled, non-inferiority phase III trial[J].eClinicalMedicine, 2022, 52:101596. DOI:10. 1016/j.eclinm. 2022. 101596.
[55]肖金波，史景红，严冬梅，等.肠道病毒71型灭活疫苗研究进展[J].中国疫苗和免疫，2024,30(04):492-500. DOI:10. 19914/j. CJVI. 2024081.
[56]Nguyen TT, Chiu CH, Lin CY, et al. Efficacy,safety, and immunogenicity of an inactivated,adjuvanted enterovirus 71 vaccine in infants and children:a multiregion, double-blind, randomised,placebo-controlled, phase 3 trial[J]. Lancet, 2022, 399(10336):1708-1717. DOI:10. 1016/s0140-6736(22)00313-0.
[57]Li Y, Zhou Y, Cheng Y, et al. Effectiveness of EVA71 vaccination in prevention of paediatric hand, foot,and mouth disease associated with EV-A71 virus infection requiring hospitalisation in Henan, China, 2017–18:a test-negative case-control study[J]. Lancet Child Adolesc Health, 2019, 3(10):697-704. DOI:10. 1016/s2352-4642(19)30185-3.
[58]Wu JT, Jit M, Zheng Y, et al. Routine pediatric enterovirus 71 vaccination in China:a cost-effectiveness analysis[J]. PLoS Med, 2016, 13(3):e1001975.DOI:10. 1371/journal. pmed. 1001975.
[59]Chiu ML, Luo ST, Chen YY, et al. Establishment of Asia-Pacific network for enterovirus surveillance[J].Vaccine, 2020, 38(1):1-9. DOI:10. 1016/j.vaccine. 2019. 09. 111.
[60]Holm-Hansen CC, Midgley SE, Schj?rring S, et al.The importance of enterovirus surveillance in a Postpolio world[J]. Clin Microbiol Infect, 2017, 23(6):352-354. DOI:10. 1016/j. cmi. 2017. 02. 010.
[61]王佶，陈操.基于“六全一关联”框架的病毒变异全景图构建与应用[J].病毒学报，2025,41(04):1001-1006.DOI:10. 13242/j. cnki. bingduxuebao. 250052.
[62]温梅花，张红英，谢金莲.健康教育在手足口病防控和管理中的作用[J].黑龙江中医药，2024,53(01):14 6-148.
[63]刘贵会，陈春，刘敏.个性化护理配合健康教育在小儿手足口病感染防控护理中的应用研究[J].中外医学研究，2020,18(12):83-85. DOI:10. 14033/j. cnki.cfmr. 2020. 12. 036.
[64]王小莉，魏洪鑫，贾蕾，等.我国手足口病经济负担研究概况[J].中华流行病学杂志，2020,41(02):273-279.DOI:10. 3760/cma. j. issn. 0254-6450. 2020. 02. 023.
[65]汪慧，蒋书琴，陈纯，等.广州市手足口病不同分型门诊患者疾病经济负担分析[J].现代预防医学，2022, 49(01):152-157.
[66]陈春艳，仇丽霞，赵执扬，等.深圳市宝安区手足口病经济负担及影响因素[J].护理研究，2024,38(07):1262-1268.
[67]金芳，夏世文.新生儿中枢神经系统肠道病毒感染的研究进展[J].中国医药导报，2023,20(23):47-51. DOI:10. 20047/j. issn1673-7210. 2023. 23. 09.
[68]Chang LY, Lin HY, Gau SS, et al. Enterovirus A71neurologic complications and long-term sequelae[J]. J Biomed Sci, 2019, 26(1):57. DOI:10. 1186/s12929-019-0552-7.
[69]Huang CC, Liu CC, Chang YC, et al. Neurologic complications in children with enterovirus 71 infection[J]. N Engl J Med, 1999, 341(13):936-942. DOI:10. 1056/nejm199909233411302.
[70]Messacar K, Schreiner TL, Van Haren K, et al. Acute flaccid myelitis:a clinical review of US cases 2012–2015[J]. Ann Neurol, 2016, 80(3):326-338. DOI:10. 1002/ana. 24730.
[71]Han Z, Wang F, Xiao J, et al. Synergetic association between coxsackievirus A16 genotype evolution and recombinant form shifts[J]. Virus Evol, 2024, 10:vead080. DOI:10. 1093/ve/vead080.
[72]Lu H, Xiao J, Song Y, et al. Evolution, recombination and geographic spreading of global Coxsackievirus A6[J]. J Clin Virol, 2024, 173:105691. DOI:10. 1016/j. jcv. 2024. 105691.
[73]Xiao M, Han Z, Ma X, et al. Global evolution and transmission dynamics of enterovirus D68[J]. J Med Virol, 2025, 97(7):e70497. DOI:10. 1002/jmv. 70497.
[74]Liu Y, Sun Q, Xiao J, et al. Genetic variation and evolutionary characteristics of Echovirus 11:new variant within genotype D5 associated with neonatal death found in China[J]. Emerg Microbes Infect, 2024, 13:2361814. DOI:10. 1080/22221751. 2024. 2361814.
[75]Lindberg AM, Andersson P, Savolainen C, et al.Evolution of the genome of Human enterovirus B:incongruence between phylogenies of the VP1 and 3CD regions indicates frequent recombination within the species[J]. J Gen Virol, 2003, 84(5):1223-1235.DOI:10. 1099/vir. 0. 18971-0.
[76]Lukashev AN, Lashkevich VA, Ivanova OE, et al.Recombination in circulating Human enterovirus B:independent evolution of structural and non-structural genome regions[J]. J Gen Virol, 2005, 86(12):3281-3290. DOI:10. 1099/vir. 0. 81264-0.
[77]Xiao J, Wang J, Lu H, et al. Genomic epidemiology and transmission dynamics of global coxsackievirus B4[J]. Viruses, 2023, 15(2):569. DOI:10. 3390/v15020569.
[78]Li X, Lu H, Sun Q, et al. Transmission of recombinant enterovirus A76(EV-A76)in Xinjiang Uighur autonomous region of China[J]. Emerg Microbes Infect, 2023, 12:2149350. DOI:10. 1080/22221751. 2022. 2149350.
[79]Cong R, Xiao J, Ji T, et al. Genetic characterization and molecular epidemiological analysis of enterovirus C99 in China[J]. J Med Virol, 2024, 96(2):e29449.DOI:10. 1002/jmv. 29449.
[80]Lu H, Hong M, Zhang Y, et al. A novel interspecies recombinant enterovirus(Enterovirus A120)isolated from a case of acute flaccid paralysis in China[J]. Emerg Microbes Infect, 2020, 9(1):1733-1743. DOI:10. 1080/22221751. 2020. 1796527.
[81]宋娟，肖金波，韩俊，等.全基因组分析揭示A组肠道病毒型间重组的复杂模式[J].病毒学报，2019,35(0 3):454-460. DOI:10. 13242/j. cnki.bingduxuebao. 003537.
[82]Jian F, Wang J, Yisimayi A, et al. Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN. 1[J]. Nature, 2025, 637(8047):921-929. DOI:10. 1038/s41586-024-08315-x.
[83]Focosi D, McConnell S, Casadevall A. The Omicron variant of concern:Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies[J]. Drug Resist Updat, 2022,65:100882. DOI:10. 1016/j. drup. 2022. 100882.
基本信息:
DOI：10.13242/j.cnki.bingduxuebao.250287
中图分类号:R512.5
引用信息:
[1]肖金波,张勇.肠道病毒病的防控现状、核心难题及创新方向[J].病毒学报,2025,41(06):1691-1701.DOI:10.13242/j.cnki.bingduxuebao.250287.
基金信息:
传染病溯源预警与智能决策全国重点实验室资助（项目号：ZDGWNLJS25-36）,题目：未知及新发病原体监测及预测预警技术研究~~